Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | DK | 14 Jul 2021 | |
Metastatic Colorectal Carcinoma | Phase 2 | NL | 14 Jul 2021 | |
Metastatic Colorectal Carcinoma | Phase 2 | KR | 14 Jul 2021 | |
Metastatic Colorectal Carcinoma | Phase 2 | ES | 14 Jul 2021 | |
Metastatic Colorectal Carcinoma | Phase 2 | GB | 14 Jul 2021 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | DK | 14 Jul 2021 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | NL | 14 Jul 2021 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | KR | 14 Jul 2021 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | ES | 14 Jul 2021 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | GB | 14 Jul 2021 |
Phase 1 | - | tvjkmektfr(mklbsqvwwk) = AEs were generally mild to moderate (i.e., G1-2) across both parts. Most common AEs ≥ G3 in Part A were asthenia (6.5%), AST elevation and pneumonia (each 4.8%), whereas pneumonia, pneumonitis (each 10.3%), neutro- and lymphocytopenia (each 7.7%) were most frequent in Part B. DLTs were febrile neutropenia G3 (45 mg), CRS G3 (130 mg) and pneumonitis G3 (500 mg plus ATZ); a MTD was not reached. hbgqbjuvmb (votauwdldu ) | - | 18 Sep 2020 | |||